File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Long-term effect of Helicobacter pylori eradication on colorectal cancer incidences

TitleLong-term effect of Helicobacter pylori eradication on colorectal cancer incidences
Authors
Keywordsclarithromycin-containing triple therapy
colorectal cancer
epidemiology
Helicobacter pylori
standardized incidence ratio
Issue Date6-May-2023
PublisherSAGE Publications
Citation
Therapeutic Advances in Gastroenterology, 2023, v. 16 How to Cite?
Abstract

Background:

There is evidence supporting the association between Helicobacter pylori infection and colorectal cancer (CRC), but whether H. pylori eradication reduces the risk of CRC is still unknown.

Objectives:

To compare the incidence of CRC in subjects who had received H. pylori eradication therapy with general population.

Design:

A population-based retrospective cohort study.

Methods:

This study included all H. pylori-infected subjects who had received their first course of clarithromycin-containing triple therapy in 2003–2015 in Hong Kong. We compared the observed incidences of CRC in this H. pylori eradicated cohort with the expected incidences in the age- and sex-matched general population. The standardized incidence ratio (SIR) with 95% confidence interval (CI) was computed.

Results:

Among 96,572 H. pylori-eradicated subjects with a median follow-up of 9.7 years, 1417 (1.5%) developed CRC. Primary analysis showed no significant difference in the observed and expected incidences of CRC (SIR: 1.03, 95% CI: 0.97–1.09). However, when stratified according to the follow-up period, higher incidence of CRC was only observed in the first 5 years after eradication (SIR: 1.47, 95% CI: 1.39–1.55), but it was lower (SIR: 0.85, 95% CI: 0.74–0.99) than general population after 11 years. When stratified by tumor location, the observed incidence was higher for colon (SIR: 1.20, 95% CI: 1.12–1.29) but lower for rectal cancer (SIR: 0.90, 95% CI: 0.81–0.999) among H. pylori-eradicated subjects.

Conclusions:

H. pylori-infected subjects appeared to have a higher incidence of CRC initially, which declined progressively to a level lower than general population 10 years after H. pylori eradication, particularly for rectal cancer.


Persistent Identifierhttp://hdl.handle.net/10722/340849
ISSN
2021 Impact Factor: 4.802
2020 SCImago Journal Rankings: 1.278

 

DC FieldValueLanguage
dc.contributor.authorGuo, CG-
dc.contributor.authorZhang, FF-
dc.contributor.authorJiang, F-
dc.contributor.authorWang, LL-
dc.contributor.authorChen, YJ-
dc.contributor.authorZhang, WX-
dc.contributor.authorZhou, AN-
dc.contributor.authorZhang, ST-
dc.contributor.authorLeung, WK-
dc.date.accessioned2024-03-11T10:47:46Z-
dc.date.available2024-03-11T10:47:46Z-
dc.date.issued2023-05-06-
dc.identifier.citationTherapeutic Advances in Gastroenterology, 2023, v. 16-
dc.identifier.issn1756-283X-
dc.identifier.urihttp://hdl.handle.net/10722/340849-
dc.description.abstract<h3>Background:</h3><p>There is evidence supporting the association between <em>Helicobacter pylori</em> infection and colorectal cancer (CRC), but whether <em>H. pylori</em> eradication reduces the risk of CRC is still unknown.</p><h3>Objectives:</h3><p>To compare the incidence of CRC in subjects who had received <em>H. pylori</em> eradication therapy with general population.</p><h3>Design:</h3><p>A population-based retrospective cohort study.</p><h3>Methods:</h3><p>This study included all <em>H. pylori</em>-infected subjects who had received their first course of clarithromycin-containing triple therapy in 2003–2015 in Hong Kong. We compared the observed incidences of CRC in this <em>H. pylori</em> eradicated cohort with the expected incidences in the age- and sex-matched general population. The standardized incidence ratio (SIR) with 95% confidence interval (CI) was computed.</p><h3>Results:</h3><p>Among 96,572 <em>H. pylori</em>-eradicated subjects with a median follow-up of 9.7 years, 1417 (1.5%) developed CRC. Primary analysis showed no significant difference in the observed and expected incidences of CRC (SIR: 1.03, 95% CI: 0.97–1.09). However, when stratified according to the follow-up period, higher incidence of CRC was only observed in the first 5 years after eradication (SIR: 1.47, 95% CI: 1.39–1.55), but it was lower (SIR: 0.85, 95% CI: 0.74–0.99) than general population after 11 years. When stratified by tumor location, the observed incidence was higher for colon (SIR: 1.20, 95% CI: 1.12–1.29) but lower for rectal cancer (SIR: 0.90, 95% CI: 0.81–0.999) among <em>H. pylori</em>-eradicated subjects.</p><h3>Conclusions:</h3><p><em>H. pylori</em>-infected subjects appeared to have a higher incidence of CRC initially, which declined progressively to a level lower than general population 10 years after <em>H. pylori</em> eradication, particularly for rectal cancer.</p>-
dc.languageeng-
dc.publisherSAGE Publications-
dc.relation.ispartofTherapeutic Advances in Gastroenterology-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectclarithromycin-containing triple therapy-
dc.subjectcolorectal cancer-
dc.subjectepidemiology-
dc.subjectHelicobacter pylori-
dc.subjectstandardized incidence ratio-
dc.titleLong-term effect of Helicobacter pylori eradication on colorectal cancer incidences-
dc.typeArticle-
dc.identifier.doi10.1177/17562848231170943-
dc.identifier.scopuseid_2-s2.0-85158168857-
dc.identifier.volume16-
dc.identifier.eissn1756-2848-
dc.identifier.issnl1756-283X-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats